Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Dec 16, 2023 12:23pm
184 Views
Post# 35788253

RE:RE:RE:RE:RE:RE:RE:RE:RE:Fair Market Value

RE:RE:RE:RE:RE:RE:RE:RE:RE:Fair Market Value
Problem is Noteable is that you make it personal. All I did and the same with many others state that we did not think it possible for AA with the number of patients we have had in our trials. What was wrong with that, all it was is another point of view and you still could not find a trial that got AA with that small number of patients even after you kept bashing me. I never bashed you, all I did was ask if you could point me to a trial, any trial that received AA with our small patient number and then you change the subject ot breakthrough therapy or ods but never answerered the question. We all hold out for that but reality is it is not going to happen IMO and if it was we would have already had it for the panc as it has been a year and does not take the fda a year to grant AA. NO one knows for sure what is going on even you as it is all speculation and everyone here knows it.
<< Previous
Bullboard Posts
Next >>